PIM
MRSN

Platinum Investment Management’s Mersana Therapeutics MRSN Stock Holding History

Platinum Investment Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,612
Closed -$1.19M – 152
2023
Q1 		$1.19M Hold
11,612
– – 0.04% 96
2022
Q4 		$1.7M Hold
11,612
– – 0.06% 85
2022
Q3 		$1.96M Sell
11,612
-8,207
-41% -$1.33M 0.08% 77
2022
Q2 		$2.29M Hold
19,819
– – 0.09% 78
2022
Q1 		$1.98M Hold
19,819
– – 0.06% 84
2021
Q4 		$3.08M Buy
19,819
+15,383
+347% +$2.99M 0.09% 79
2021
Q3 		$1.05M Hold
4,436
– – 0.03% 116
2021
Q2 		$1.51M Hold
4,436
– – 0.03% 106
2021
Q1 		$1.79M Hold
4,436
– – 0.04% 92
2020
Q4 		$2.95M Hold
4,436
– – 0.07% 73
2020
Q3 		$2.06M Hold
4,436
– – 0.05% 79
2020
Q2 		$2.6M Buy
+4,436
New +$1.51M 0.06% 74

Other funds holding MRSN

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Platinum Investment Management's MRSN Position: Q2 2023 in Review

Platinum Investment Management sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 11,612 shares — an estimated $1.19M sold.

Platinum Investment Management first reported a position in MRSN in Q2 2020 and held it in 12 quarters. The position peaked at $3.08M in Q4 2021. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

  • Platinum Investment Management reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Platinum Investment Management sold 11,612 Mersana Therapeutics shares in Q2 2023, an estimated $1.19M.
  • Platinum Investment Management first reported a position in Mersana Therapeutics in Q2 2020 and held it in 12 quarters.
  • Platinum Investment Management's Mersana Therapeutics position peaked at $3.08M in Q4 2021.
  • 147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on Platinum Investment Management's 13F filing for Q2 2023, filed 11 Aug 2023.